Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication.
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 31 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12 and 12 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Unspecified Cancer, Solid Tumor, Hematological Tumor, Lymphoma, Breast Cancer, Burkitt Lymphoma, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Multiple Myeloma (Kahler Disease), Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Blood Cancer, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Leukemia, Lung Cancer, Medulloblastoma, Metastatic Brain Tumor, Neuroblastoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Retinoblastoma, Small-Cell Lung Cancer, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and Triple-Negative Breast Cancer (TNBC).
The latest report Myc Proto Oncogene Protein – Drugs In Development, 2022, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Myc (c-Myc) protein encoded by Myc gene, a regulator gene that code for a transcription factor. The protein plays a role in cell cycle progression, apoptosis and cellular transformation. Myc protein is a transcription factor that activates expression of many genes through binding enhancer box sequences and recruiting histone acetyltransferases. It also acts as a transcriptional repressor. By binding Miz-1 transcription factor and displacing the p300 co-activator, it inhibits expression of Miz-1 target genes. In addition, myc has a direct role in the control of DNA replication. Myc is a proto-oncogene and it often upregulates in many types of cancers. Myc over expression stimulates gene amplification presumably through DNA over-replication.
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 31 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 12 and 12 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Unspecified Cancer, Solid Tumor, Hematological Tumor, Lymphoma, Breast Cancer, Burkitt Lymphoma, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Multiple Myeloma (Kahler Disease), Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Blood Cancer, Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Leukemia, Lung Cancer, Medulloblastoma, Metastatic Brain Tumor, Neuroblastoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Retinoblastoma, Small-Cell Lung Cancer, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) and Triple-Negative Breast Cancer (TNBC).
The latest report Myc Proto Oncogene Protein – Drugs In Development, 2022, outlays comprehensive information on the Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
- The report reviews Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics and enlists all their major and minor projects
- The report assesses Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Overview
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Companies Involved in Therapeutics Development
Anima Biotech Inc
Arrakis Therapeutics Inc
Arvinas Inc
Biogenera SpA
Ceptur Therapeutics Inc
Cothera Bioscience Pty Ltd
Erasca Inc
Escend Pharmaceuticals Inc
Gibson Oncology LLC
Kintor Pharmaceutical Ltd
Kronos Bio Inc
MecRx Pty Ltd
Omega Therapeutics Inc
OncoViRx LLC
Origenis GmbH
Peptomyc SL
PYC Therapeutics Ltd
Recursion Pharmaceuticals Inc
Sapience Therapeutics Inc
SyntheX Inc
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Drug Profiles
Amy-22 – Drug Profile
Product Description
Mechanism Of Action
History of Events
BGA-003 – Drug Profile
Product Description
Mechanism Of Action
Drugs to Inhibit MYC for Breast Cancer – Drug Profile
Product Description
Mechanism Of Action
ERAS-11 – Drug Profile
Product Description
Mechanism Of Action
ES-4000 – Drug Profile
Product Description
Mechanism Of Action
GT-19077 – Drug Profile
Product Description
Mechanism Of Action
History of Events
GT-19630 – Drug Profile
Product Description
Mechanism Of Action
Myc – Drug Profile
Product Description
Mechanism Of Action
History of Events
MYC – Drug Profile
Product Description
Mechanism Of Action
MYC (Oncology) – Drug Profile
Product Description
Mechanism Of Action
History of Events
NOV-1701 – Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides to Inhibit MYC for Hepatocellular Carcinoma and Non Small Cell Lung Cancer – Drug Profile
Product Description
Mechanism Of Action
OMO-101 – Drug Profile
Product Description
Mechanism Of Action
OMO-103 – Drug Profile
Product Description
Mechanism Of Action
History of Events
OTX-2002 – Drug Profile
Product Description
Mechanism Of Action
History of Events
PC-002p – Drug Profile
Product Description
Mechanism Of Action
REC-0162977 – Drug Profile
Product Description
Mechanism Of Action
REC-841 – Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Target c-Myc for Multiple Myeloma – Drug Profile
Product Description
Mechanism Of Action
Small Molecules 3 to Inhibit C-Myc for Unspecified Cancer – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit c-Myc for Oncology – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit C-Myc for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit C-Myc for Unspecified Cancer – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit cMYC and PTEN for Unspecified Cancers – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit cMyc for Oncology – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit MYC and TOP1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
STX-300 – Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Inhibit C-Myc for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide to Inhibit cMyc for Hematological Tumor and Solid Tumor – Drug Profile
Product Description
Mechanism Of Action
Target 1 (PPI Modulator) – Drug Profile
Product Description
Mechanism Of Action
History of Events
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Dormant Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Discontinued Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Product Development Milestones
Featured News & Press Releases
Jun 23, 2022: Omega Therapeutics to present new preclinical data for the first epigenomic controller, OTX-2002, for hepatocellular carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
Jun 15, 2022: Omega Therapeutics announces submission of Investigational New Drug application for OTX-2002, an Omega Epigenomic Controller, for MYC driven hepatocellular carcinoma
Apr 08, 2022: Omega Therapeutics presents preclinical data on OTX-2002, first-in-class epigenomic controller, as potential treatment for hepatocellular carcinoma at the AACR Annual Meeting 2022
Mar 08, 2022: Omega Therapeutics to present preclinical data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022
May 06, 2021: Peptomyc SL announces treatment of first patient with its lead compound OMO-103 in a phase I/II clinical trial
Mar 17, 2021: Omomyc, a drug developed in Vall d'Hebron, is coming to the clinical trial
Jul 30, 2020: VHIO and home-grown spin-off Peptomyc S.L receive further funding to bring Omomyc closer to the clinic
Jun 22, 2020: Pioneer Pharmaceuticals released the latest research results of c-Myc inhibitors at the AACR annual meeting
Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translational Medicine and the news
Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc
Mar 14, 2019: A new approach to drugging a difficult cancer target
Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer
Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Overview
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Companies Involved in Therapeutics Development
Anima Biotech Inc
Arrakis Therapeutics Inc
Arvinas Inc
Biogenera SpA
Ceptur Therapeutics Inc
Cothera Bioscience Pty Ltd
Erasca Inc
Escend Pharmaceuticals Inc
Gibson Oncology LLC
Kintor Pharmaceutical Ltd
Kronos Bio Inc
MecRx Pty Ltd
Omega Therapeutics Inc
OncoViRx LLC
Origenis GmbH
Peptomyc SL
PYC Therapeutics Ltd
Recursion Pharmaceuticals Inc
Sapience Therapeutics Inc
SyntheX Inc
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Drug Profiles
Amy-22 – Drug Profile
Product Description
Mechanism Of Action
History of Events
BGA-003 – Drug Profile
Product Description
Mechanism Of Action
Drugs to Inhibit MYC for Breast Cancer – Drug Profile
Product Description
Mechanism Of Action
ERAS-11 – Drug Profile
Product Description
Mechanism Of Action
ES-4000 – Drug Profile
Product Description
Mechanism Of Action
GT-19077 – Drug Profile
Product Description
Mechanism Of Action
History of Events
GT-19630 – Drug Profile
Product Description
Mechanism Of Action
Myc – Drug Profile
Product Description
Mechanism Of Action
History of Events
MYC – Drug Profile
Product Description
Mechanism Of Action
MYC (Oncology) – Drug Profile
Product Description
Mechanism Of Action
History of Events
NOV-1701 – Drug Profile
Product Description
Mechanism Of Action
Oligonucleotides to Inhibit MYC for Hepatocellular Carcinoma and Non Small Cell Lung Cancer – Drug Profile
Product Description
Mechanism Of Action
OMO-101 – Drug Profile
Product Description
Mechanism Of Action
OMO-103 – Drug Profile
Product Description
Mechanism Of Action
History of Events
OTX-2002 – Drug Profile
Product Description
Mechanism Of Action
History of Events
PC-002p – Drug Profile
Product Description
Mechanism Of Action
REC-0162977 – Drug Profile
Product Description
Mechanism Of Action
REC-841 – Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Target c-Myc for Multiple Myeloma – Drug Profile
Product Description
Mechanism Of Action
Small Molecules 3 to Inhibit C-Myc for Unspecified Cancer – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit c-Myc for Oncology – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit C-Myc for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit C-Myc for Unspecified Cancer – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit cMYC and PTEN for Unspecified Cancers – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit cMyc for Oncology – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit MYC and NFKB for Lymphomas and Leukemias – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit MYC and TOP1 for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
STX-300 – Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Inhibit C-Myc for Oncology – Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic Peptide to Inhibit cMyc for Hematological Tumor and Solid Tumor – Drug Profile
Product Description
Mechanism Of Action
Target 1 (PPI Modulator) – Drug Profile
Product Description
Mechanism Of Action
History of Events
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Dormant Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Discontinued Products
Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) – Product Development Milestones
Featured News & Press Releases
Jun 23, 2022: Omega Therapeutics to present new preclinical data for the first epigenomic controller, OTX-2002, for hepatocellular carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
Jun 15, 2022: Omega Therapeutics announces submission of Investigational New Drug application for OTX-2002, an Omega Epigenomic Controller, for MYC driven hepatocellular carcinoma
Apr 08, 2022: Omega Therapeutics presents preclinical data on OTX-2002, first-in-class epigenomic controller, as potential treatment for hepatocellular carcinoma at the AACR Annual Meeting 2022
Mar 08, 2022: Omega Therapeutics to present preclinical data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022
May 06, 2021: Peptomyc SL announces treatment of first patient with its lead compound OMO-103 in a phase I/II clinical trial
Mar 17, 2021: Omomyc, a drug developed in Vall d'Hebron, is coming to the clinical trial
Jul 30, 2020: VHIO and home-grown spin-off Peptomyc S.L receive further funding to bring Omomyc closer to the clinic
Jun 22, 2020: Pioneer Pharmaceuticals released the latest research results of c-Myc inhibitors at the AACR annual meeting
Apr 01, 2019: First published demonstration of the success of Myc inhibition by Omomyc mini-protein hits Science Translational Medicine and the news
Mar 26, 2019: Preclinical validation of new cancer inhibitor from EIT Health-supported Peptomyc
Mar 14, 2019: A new approach to drugging a difficult cancer target
Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer
Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Anima Biotech Inc, 2022
Pipeline by Arrakis Therapeutics Inc, 2022
Pipeline by Arvinas Inc, 2022
Pipeline by Biogenera SpA, 2022
Pipeline by Ceptur Therapeutics Inc, 2022
Pipeline by Cothera Bioscience Pty Ltd, 2022
Pipeline by Erasca Inc, 2022
Pipeline by Escend Pharmaceuticals Inc, 2022
Pipeline by Gibson Oncology LLC, 2022
Pipeline by Kintor Pharmaceutical Ltd, 2022
Pipeline by Kronos Bio Inc, 2022
Pipeline by MecRx Pty Ltd, 2022
Pipeline by Omega Therapeutics Inc, 2022
Pipeline by OncoViRx LLC, 2022
Pipeline by Origenis GmbH, 2022
Pipeline by Peptomyc SL, 2022
Pipeline by PYC Therapeutics Ltd, 2022
Pipeline by Recursion Pharmaceuticals Inc, 2022
Pipeline by Sapience Therapeutics Inc, 2022
Pipeline by SyntheX Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Anima Biotech Inc, 2022
Pipeline by Arrakis Therapeutics Inc, 2022
Pipeline by Arvinas Inc, 2022
Pipeline by Biogenera SpA, 2022
Pipeline by Ceptur Therapeutics Inc, 2022
Pipeline by Cothera Bioscience Pty Ltd, 2022
Pipeline by Erasca Inc, 2022
Pipeline by Escend Pharmaceuticals Inc, 2022
Pipeline by Gibson Oncology LLC, 2022
Pipeline by Kintor Pharmaceutical Ltd, 2022
Pipeline by Kronos Bio Inc, 2022
Pipeline by MecRx Pty Ltd, 2022
Pipeline by Omega Therapeutics Inc, 2022
Pipeline by OncoViRx LLC, 2022
Pipeline by Origenis GmbH, 2022
Pipeline by Peptomyc SL, 2022
Pipeline by PYC Therapeutics Ltd, 2022
Pipeline by Recursion Pharmaceuticals Inc, 2022
Pipeline by Sapience Therapeutics Inc, 2022
Pipeline by SyntheX Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
